Tenders Are Invited For Supply, Implementation And Maintenance Of A Validated Total Solution For Scid And Sma Screening For Multiple Laboratories

The Neonatal Heel Prick Screening (Nhs) Is A National Screening Program That Is Carried Out On Newborns In The First Week After Birth. In The Netherlands (European And Caribbean Netherlands), Approximately 170,000 Newborns Receive The Heel Prick Every Year. The Heel Prick Screening Is The Longest-Running National Screening Program In Public Health Care. The Analysis Of The Heel Prick Blood Currently Provides Important Information About Twenty-Seven Rare, Often Hereditary, Serious Conditions. From 2026, The Blood Test Will Be Carried Out By Three Screening Laboratories, Of Which The Rivm-Gzb Screening Laboratory Functions As A Reference Laboratory. The Screening Laboratories Are Responsible For The Analysis Of The Heel Prick Blood Sample And Timely Reporting Of The Results. From January 2021, All Screening Laboratories Will Use A Total Solution For Screening For Scid. From June 1, 2022, Sma Has Also Been Added To The Program And The Laboratories Will Screen With A Multiplex Total Solution That Can Screen For Both Scid And Sma. In Addition, It Is Possible That In The Coming Years It Will Be Decided That Screening For This Tender Procedure Concerns An Order For The Supply, Implementation And Maintenance Of A Validated Total Solution For Scid And Sma Screening For The Screening Laboratories. The Purpose Of This European Tender Is To Conclude An Agreement With One Contractor, According To The Principle Of Reagent Rental, Whereby The Supplier Remains The Owner Of The Equipment. The Contractor Will Be Fully Responsible For Delivering, Implementing And Continuously Making Available The Total Solution And Providing Related Services In Accordance With The Specifications Laid Down In The Tender Documents.